Should investors buy Smith & Nephew shares today?

Smith & Nephew shares were crushed during the Covid-19 pandemic and remain well below their highs. Is now the time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businesswoman calculating finances in an office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE: SN.) shares have taken a big hit over the last few years. Before Covid, shares in the orthopaedics company were trading around the £20 mark. Today however, they can be picked up for around £12.

Is this a great buying opportunity for long-term investors? Let’s take a look.

Why the share price fell

Smith & Nephew has certainly faced its fair share of challenges in recent years. During the Covid pandemic, many elective surgeries were postponed. This had a big impact on the company’s sales.

The firm has also faced supply chain issues. In recent years, hip and knee implants have become unexpected casualties of raw material shortages.

On top of this, Smith & Nephew has had to deal with inflationary pressures. Margins have been hit by higher commodity and wage costs.

Finally, growth has been also impacted by currency issues, as the company reports in US dollars.

Overall, the operating environment has been very challenging.

Improving outlook

It now looks like Smith & Nephew is starting to turn the corner however.

In a recent trading update, the healthcare company advised that for 2023, it expects revenue growth of 5-6%, above the level of 4.7% reported for 2022.

It also said it expects its medium-term trading profit margin to expand to at least 20% in 2025, versus 17.3% in 2022, on the back of productivity improvements.

We expect to deliver both faster revenue growth and margin expansion in the coming year, and are setting a solid foundation for our mid-term ambitions as we transform to a consistently higher growth company.

Smith & Nephew CEO Deepak Nath

This is all very encouraging.

Looking further out, the prospects for the company remain attractive, to my mind.

This is a business that is well-placed to benefit from the world’s ageing population. Higher numbers of over 65s globally should drive demand for orthopaedic products.

According to Precedence Research, the market for knee implants is expected to grow by around 6% a year between now and 2030.

Valuation

As for the stock’s valuation, it’s relatively attractive right now, to my mind.

Currently, analysts expect Smith & Nephew to generate earnings per share of 85.3 cents for 2023. That puts the stock on a forward-looking price-to-earnings (P/E) ratio of around 17.

Now that multiple is higher than the FTSE 100 average. However, it’s significantly lower than that of US-listed rival Stryker, which currently has a P/E ratio of about 26.

At the current valuation, I think there’s potential for multiple appreciation if the company can demonstrate that business performance is improving and its transformation plan is working.

Attractive risk/reward

Of course, there are risks here. In the company’s recent results, it noted that it will continue to face macroeconomic headwinds in 2023.

It’s worth pointing out that Smith & Nephew did not recently increase its dividend for 2022. This suggests that management is a little cautious about the future.

Overall however, I like the risk/reward proposition right now. At the current share price, I see the stock as a buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should I buy National Grid shares for the big dividend before it’s too late?

This year's price weakness has left National Grid shares on what looks like a tempting valuation. I hope it doesn't…

Read more »